IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Myriad Genetics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Business Wire

LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Myriad Genetics, Inc. (“Myriad” or “the Company”) (NASDAQ: MYGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between September 2, 2016 and August 13, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before November 26, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Myriad failed to gather evidence to demonstrate benefits of GeneSight testing. The FDA requested changes to GeneSight and questioned its value. The Company engaged in ongoing discussions with the FDA about these changes. Myriad’s acquisition of Counsyl led to a material negative impact on the Company’s revenue. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Myriad, investors suffered damages.

Join the case to recover your losses.